Eli Lilly experimental obesity drug helped patients lose up to 24% of their weight, study says


In this article

Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain.
Cristina Arias | Cover | Getty Images

Eli Lilly’s experimental drug helped patients lose up to 24% of their weight after almost a year, the highest reduction seen in the obesity treatment space to date, according to new mid-stage clinical trial results released Monday. 

The phase two trial followed 338 adults who were obese or overweight and either received the pharmaceutical company’s injection, retatrutide, or a placebo each week. 

Patients who took a 12-milligram dose of retatrutide lost 17.5% of their body weight, or 41 pounds, on average after 24 weeks, compared with 1.6% for those who received the placebo. 

Patients lost 24.2%, or 58 pounds, on average after 48 weeks. Those who took the placebo lost 2.1% of their body weight after that same time period.

The trial’s researchers said average weight loss did not appear to plateau after 48 weeks, suggesting a longer study could show even more. Eli Lilly is currently recruiting patients for a phase three trial.

That data suggests Eli Lilly’s retatrutide is the “most effective anti-obesity med to date,” Michael Weintraub, an endocrinologist at NYU Langone Health, said in a Twitter post

Eli Lilly’s other obesity drug Mounjaro, which is approved for type 2 diabetes, has helped patients lose up to 21% of their weight in clinical trials.

Novo Nordisk’s Wegovy, cleared for weight loss, has shown up to 15% weight loss in trials. 

Like Wegovy and Mounjaro, Eli Lilly’s retatrutide is a weekly injection that changes the way patients eat and leads to decreased appetite by mimicking certain hormones in the gut.

But Wegovy only mimics one hunger-regulating hormone called GLP-1, while Mounjaro mimics GLP-1 and another hormone called GIP.

Retatrutide mimics three different hunger-regulating hormones: GLP-1, GIP and glucagon. That appears to have more potent effects on a person’s appetite and satisfaction with food. 

Articles You May Like

Student loan bills resume for 40 million Americans. How it could shake the economy
Biden ESG rule survives challenge in court. ‘Tonal shift’ may be biggest victory, lawyer says
Blue Origin, Sierra Space weigh future of Orbital Reef space station as partnership turns rocky
Bill Ackman believes the 10-year Treasury yield could approach 5% soon
Fed’s Neel Kashkari sees 40% chance of ‘meaningfully higher’ interest rates